|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0019163,
umls-concept:C0019168,
umls-concept:C0019169,
umls-concept:C0023884,
umls-concept:C0087111,
umls-concept:C0681842,
umls-concept:C0871261,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C1709793,
umls-concept:C2911692
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2007-12-6
|
|
pubmed:abstractText |
We aimed to evaluate serum hepatitis B surface antigen (HBsAg) quantitation as a surrogate marker for covalently closed circular DNA (cccDNA) and intrahepatic hepatitis B virus (HBV) DNA, and as a predictor of sustained virologic response to peginterferon and lamivudine combination therapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiviral Agents,
http://linkedlifedata.com/resource/pubmed/chemical/DNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Carriers,
http://linkedlifedata.com/resource/pubmed/chemical/Hepatitis B Surface Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/Lamivudine,
http://linkedlifedata.com/resource/pubmed/chemical/Polyethylene Glycols,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Reverse Transcriptase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b,
http://linkedlifedata.com/resource/pubmed/chemical/peginterferon alfa-2b
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
1542-7714
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
5
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1462-8
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18054753-Adult,
pubmed-meshheading:18054753-Antiviral Agents,
pubmed-meshheading:18054753-Biopsy,
pubmed-meshheading:18054753-DNA, Viral,
pubmed-meshheading:18054753-Drug Carriers,
pubmed-meshheading:18054753-Drug Therapy, Combination,
pubmed-meshheading:18054753-Female,
pubmed-meshheading:18054753-Follow-Up Studies,
pubmed-meshheading:18054753-Hepatitis B, Chronic,
pubmed-meshheading:18054753-Hepatitis B Surface Antigens,
pubmed-meshheading:18054753-Hepatitis B virus,
pubmed-meshheading:18054753-Humans,
pubmed-meshheading:18054753-Interferon-alpha,
pubmed-meshheading:18054753-Lamivudine,
pubmed-meshheading:18054753-Liver,
pubmed-meshheading:18054753-Male,
pubmed-meshheading:18054753-Polyethylene Glycols,
pubmed-meshheading:18054753-Polymerase Chain Reaction,
pubmed-meshheading:18054753-Recombinant Proteins,
pubmed-meshheading:18054753-Reverse Transcriptase Inhibitors,
pubmed-meshheading:18054753-Sensitivity and Specificity,
pubmed-meshheading:18054753-Treatment Outcome
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.
|
|
pubmed:affiliation |
Department of Medicine and Therapeutics, and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China. hlychan@cuhk.edu.hk
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
